In addition, to explore the clinical diagnostic value of HYAL2 for glioma, receiver operating characteristic (ROC) curves were generated to evaluate the accuracy of HYAL2 as a glioma prognostic factor in TCGA and CGGA (mRNA-array_301, mRNAseq_325 and mRNAseq_693) datasets. This evidence concerns the gene HYAL2 and central nervous system cancer.